ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $243,464 | +4.9% | 2,600 | 0.0% | 0.62% | -5.0% |
| Q2 2023 | $232,050 | -84.1% | 2,600 | -80.9% | 0.66% | -82.1% |
| Q1 2023 | $1,458,192 | -72.3% | 13,600 | -73.3% | 3.67% | -57.8% |
| Q3 2022 | $5,266,000 | +13.9% | 51,000 | +29.4% | 8.70% | +60.4% |
| Q1 2022 | $4,624,000 | -50.0% | 39,400 | -44.0% | 5.42% | +164.6% |
| Q2 2021 | $9,248,000 | -22.3% | 70,300 | -23.9% | 2.05% | -29.2% |
| Q1 2021 | $11,899,000 | -1.9% | 92,325 | +27.0% | 2.90% | +39.7% |
| Q4 2020 | $12,125,000 | +8.1% | 72,700 | 0.0% | 2.07% | -47.2% |
| Q3 2020 | $11,219,000 | +30.3% | 72,700 | +24.9% | 3.93% | -25.8% |
| Q2 2020 | $8,608,000 | +781.1% | 58,200 | +601.2% | 5.30% | +358.0% |
| Q1 2019 | $977,000 | – | 8,300 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |